Shares of Sono-Tek Corp plunged to $5.85, shedding nearly 18% in a single session after the ultrasonic coating equipment maker posted second-quarter results that fell short on both earnings and revenue, raising questions about whether niche bright spots can offset broader softness. Sono-Tek's Medical Boom Couldn't Save It From an 18% Rout — Is the Market Punishing a Timing Problem or a Structural One?
Shares of Sono-Tek Corp cratered 18% to $5.85 after the ultrasonic coating equipment maker reported second-quarter results that missed Wall Street targets on both the top and bottom lines, exposing the vulnerability of a micro-cap stock trading at a lofty valuation when growth stumbles even slightly.
The Numbers Tell a Story of Stalled Momentum. Sono-Tek posted earnings of $0.02 per share, missing the $0.04 consensus by 50%.
Revenue rose just 1% to $5.23 million, while net income fell 14% to $366,000 — a stark contrast to the first half's healthier trajectory. Operating income slipped to $382,000 from $421,000 a year ago as higher operating expenses ate into gains. For a stock that had been trading at a price-to-earnings ratio above 50×, well above the electronic equipment industry median of 31.2 , any earnings shortfall was bound to be punished severely.
Medical Devices Are Thriving — But the Rest of the Business Isn't Keeping Up. Medical sales surged 209% to $3.11 million, driven by balloon and stent-coating systems.
That segment now accounts for more than half of total quarterly revenue — a remarkable shift for a company historically diversified across energy, electronics, and industrial markets. But that concentration is a double-edged sword: when medical shipment timing shifts by even one quarter, revenue swings are amplified.
Management Says Wait Until Next Year. Three post-quarter orders totaling roughly $7.19 million — expected to ship in fiscal 2028 — underpin management's argument that the shortfall is about timing, not demand. The company reiterated guidance for flat to modest fiscal 2027 revenue growth.
Combined backlog stood at $9.51 million, up 23% sequentially, reflecting improved order momentum. The question for shareholders: does a growing backlog justify patience, or does unchanged guidance in a miss quarter signal limited near-term upside?
Valuation Was Already Stretched — Now It Faces a Reset. Before today's drop, one valuation model pegged intrinsic value at just $4.49, meaning the stock was trading at a 58.6% premium even at $7.12.
Insiders sold roughly $200,000 in shares over the past year with no reported purchases , a signal that even those closest to the business weren't betting on near-term appreciation. At $5.85, Sono-Tek is closer to that intrinsic estimate — but investors will need to see the backlog convert to revenue before trusting the rebound story.